Lifotronic(SH:688389) Zheng Quan Zhi Xing·2025-07-03 16:27Overview - The core point of the announcement is the progress of the capital increase and related transactions of Shenzhen Pumen Technology Co., Ltd.'s wholly-owned subsidiary, Shenzhen Pumen Biotechnology Co., Ltd. The capital increase aims to enhance the subsidiary's financial strength and competitiveness in the consumer health sector [1][4]. Group 1: Capital Increase Details - The company approved a capital increase of 33 million RMB for its subsidiary, with the total investment from related parties reduced from 64.02 million RMB to 24.20 million RMB [1]. - The registered capital of Pumen Biotechnology will increase from 3 million RMB to 63.20 million RMB, changing the company's ownership from a wholly-owned subsidiary to a controlling subsidiary with a 56.96% stake [1][3]. Group 2: Shareholder and Management Involvement - The management is authorized to handle all matters related to the capital increase, including adjusting contributions from employee stockholding platforms and managing the partnership agreements [2]. - The capital increase involves several stakeholders, including directors, executives, and employee stockholding platforms, to create a long-term incentive system [3]. Group 3: Impact on the Company - The capital increase is expected to promote the development of the consumer health business, meet the funding needs of Pumen Biotechnology, and enhance the overall capital strength and competitiveness of the subsidiary [3]. - The transaction is structured to ensure fairness and will not adversely affect the company's financial status or independence [4].